Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michaela A E Arndt

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
FEBS Letters|December 14, 2004
Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimersMichaela A E Arndt, Jürgen Krauss, Susanna M Rybak
Current Pharmaceutical Biotechnology|August 5, 2008
Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapyJürgen Krauss, Michaela A E Arndt, Stefan Dübel, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2009
High-level production of a humanized immunoRNase fusion protein from stably transfected myeloma cellsJürgen Krauss, Evelyn Exner, Athanasios Mavratzas, et al.
Expert Opinion on Biological Therapy|December 10, 2008
Targeted therapeutic RNases (ImmunoRNases)Thomas Schirrmann, Jürgen Krauss, Michaela A E Arndt, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cellsMichaela A E Arndt, Jürgen Krauss, Bang K Vu, et al.
British Journal of Haematology|February 24, 2005
Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzymeJürgen Krauss, Michaela A E Arndt, Bang K Vu, et al.
Protein Engineering|November 6, 2003
Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragmentJürgen Krauss, Michaela A E Arndt, Andrew C R Martin, et al.
International Journal of Cancer|October 21, 2003
Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphomaMichaela A E Arndt, Jürgen Krauss, Robert Schwarzenbacher, et al.
Biochemical and Biophysical Research Communications|April 27, 2005
Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion proteinJürgen Krauss, Michaela A E Arndt, Bang K Vu, et al.
Journal of Experimental Therapeutics & Oncology|November 22, 2017
Highly efficient destruction of squamous carcinoma cells of the head and neck by photochemical internalization of RanpirnaseNora Liebers, Tim Holland-Letz, Mona Welschof, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
FEBS Letters|December 14, 2004
Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimersMichaela A E Arndt, Jürgen Krauss, Susanna M Rybak
Current Pharmaceutical Biotechnology|August 5, 2008
Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapyJürgen Krauss, Michaela A E Arndt, Stefan Dübel, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2009
High-level production of a humanized immunoRNase fusion protein from stably transfected myeloma cellsJürgen Krauss, Evelyn Exner, Athanasios Mavratzas, et al.
Expert Opinion on Biological Therapy|December 10, 2008
Targeted therapeutic RNases (ImmunoRNases)Thomas Schirrmann, Jürgen Krauss, Michaela A E Arndt, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 20, 2005
A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cellsMichaela A E Arndt, Jürgen Krauss, Bang K Vu, et al.
British Journal of Haematology|February 24, 2005
Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzymeJürgen Krauss, Michaela A E Arndt, Bang K Vu, et al.
Protein Engineering|November 6, 2003
Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragmentJürgen Krauss, Michaela A E Arndt, Andrew C R Martin, et al.
International Journal of Cancer|October 21, 2003
Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphomaMichaela A E Arndt, Jürgen Krauss, Robert Schwarzenbacher, et al.
Biochemical and Biophysical Research Communications|April 27, 2005
Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion proteinJürgen Krauss, Michaela A E Arndt, Bang K Vu, et al.
Journal of Experimental Therapeutics & Oncology|November 22, 2017
Highly efficient destruction of squamous carcinoma cells of the head and neck by photochemical internalization of RanpirnaseNora Liebers, Tim Holland-Letz, Mona Welschof, et al.
Pageof 2